COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,432 Articles (22,835 medRxiv, 8,597 bioRxiv)

Most recent first Previous |  Page 1022: Articles 10211-10220  | Next

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., Tartof, S. Y.
10.1101/2022.01.11.22269045 — Posted: 2022-01-11 Discussion: Onsite
Two viruses competition in the SIR model of epidemic spread: application to COVID-19
Trigger, S. A., Ignatov, A. M.
10.1101/2022.01.11.22269046 — Posted: 2022-01-11
Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis
Guan, J., Xi, A., Jin, D., Mou, X., Xu, Z.
10.1101/2022.01.07.22268878 — Posted: 2022-01-10
Identifying SARS-CoV-2 regional introductions and transmission clusters in real time
McBroome, J., Martin, J., de Bernardi Schneider, A., Turakhia, Y., Corbett-Detig, R.
10.1101/2022.01.07.22268918 — Posted: 2022-01-10
Strong SARS-CoV-2 N-specific CD8+ T immunity induced by engineered extracellular vesicles associates with protection from lethal infection in mice.
Ferrantelli, F., Chiozzini, C., Manfredi, F., Leone, P., Spada, M., DiVirgilio, A., Giovannelli, A., Sanchez, M., Cara, A., Michelini, Z., Federico, M.
10.1101/2022.01.10.475620 — Posted: 2022-01-10
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2
Saunders, N., Planas, D., Bolland, W. H., Rodriguez, C., Fourati, S., Buchrieser, J., Planchais, C., Prot, M., Staropoli, I., Guivel-Benhassine, F., Porrot, F., Veyer, D., Pere, H., Robillard, N., Saliba, M., Baidaliuk, A., Seve, A., Hocqueloux, L., Prazuck, T., Mouquet, H., Simon-Loriere, E., Bruel, T., Pawlotsky, J.-M., Schwartz, O.
10.1101/2022.01.07.475248 — Posted: 2022-01-10
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro
Jonsdottir, H. R., Siegrist, D., Julien, T., Padey, B., Bouveret, M., Terrier, O., Pizzorno, A., Huang, S., Samby, K., Wells, T., Boda, B., Rosa-Calatrava, M., Engler, O., Constant, S.
10.1101/2022.01.10.475377 — Posted: 2022-01-10
RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice
Phatarphekar, A., Reddy, G. V., Gokhale, A., Karanam, G., Kuchroo, P., Shinde, K., Masand, G., Pagare, S., Khadpe, N., Pai, S. S., Vijayan, V., RL, R., Reddy, K. P., Rao, P., Rao, S. H., Ramana, V.
10.1101/2022.01.07.475330 — Posted: 2022-01-10
Systematic comparison of ranking aggregation methods for gene lists in experimental results
Wang, B., Law, A., Regan, T., Parkinson, N., Cole, J., Russell, C. D., Dockrell, D. H., Gutmann, M. U., Baillie, J. K.
10.1101/2022.01.09.475491 — Posted: 2022-01-10
Putative host-derived insertions in the genome of circulating SARS-CoV-2 variants
Yang, Y., Dufault-Thompson, K., Fontenele, R. S., Jiang, X.
10.1101/2022.01.04.474799 — Posted: 2022-01-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).